Claire Meunier
Vice President of Research EngagementAs Vice President of Research Engagement at The Michael J. Fox Foundation for Parkinson's Research, Claire manages efforts related to community education and clinical trial recruitment for the research ecosystem. In this capacity, Claire leads Partners in Parkinson's, MJFF's multi-million dollar partnership with industry to inspire patients to build a care team, as well as the Foundation's thought leadership on clinical trial recruitment, including advising Foundation-funded trials on recruitment strategy and overseeing Fox Trial Finder. Prior to joining MJFF, Claire earned her MBA from...
Source: PHRMA - May 5, 2015 Category: Pharmaceuticals Authors: Ali Source Type: news
Sleep on Clinical Research
Patients are my number one priority, and the reason I do what I do.
My primary motivation to become an MD was to improve the lives of patients afflicted with illness. I entered medicine to make sick people better, alleviate their suffering, and perhaps even cure their disease. The more I learnt about the diseases that affect us and what causes them, the more I became interested in finding therapies that truly worked – by targeting treatment for every individual based on a deep understanding of their specific illness/disease. I also learnt that despite the incredible advances in medicine over the past 50 years, th...
Source: PHRMA - May 4, 2015 Category: Pharmaceuticals Authors: Ali Source Type: news
Darryl Sleep
Senior Vice President, Head of Clinical Science and Asset Strategy for the Cardiovascular and Metabolic Therapeutic Area Unit With extensive global clinical and industry experience across multiple therapeutic areas Darryl Sleep, M.D. is Senior Vice President, Head of Clinical Science and Asset Strategy for the Cardiovascular and Metabolic (CVM) Therapeutic Area Unit (TAU) at Takeda Pharmaceuticals. He leads the clinical science group as well as the program leaders within the CVM TAU that covers a wide pipeline portfolio including programs in the cardiovascular, diabetes, obesity, renal, and respiratory areas.
Dr. Sleep j...
Source: PHRMA - May 4, 2015 Category: Pharmaceuticals Authors: Ali Source Type: news
Getz on Clinical Research
Every one of us, at some point in our lives, will face the daunting challenge of having to choose between medical options for ourselves, our family and our friends. Clinical trials are playing a large and growing role among the options for patients and their health care providers to evaluate and consider. Nearly 4,000 experimental drug therapies are in active clinical trials today and that number will continue to grow as improvements are made in detecting disease, in understanding the root causes of acute and chronic illnesses, and in discovering medical innovations. And in the not-so-distant future it will be more c...
Source: PHRMA - May 4, 2015 Category: Pharmaceuticals Authors: Ali Source Type: news
Kenneth Getz
ChairmanKenneth A. Getz is the chairman of CISCRP – a nonprofit organization that he founded to educate and raise public and patient awareness of the clinical research enterprise. He is also the Director of Sponsored Research and an associate professor at the Tufts Center for the Study of Drug Development, Tufts University School of Medicine where he conducts research programs on drug development management strategies and tactics, outsourcing, global investigative site and patient recruitment practices and policies. Ken is also the founder and owner of CenterWatch, a leading publisher in the clinical trials industry ...
Source: PHRMA - May 4, 2015 Category: Pharmaceuticals Authors: Ali Source Type: news
Letvak on Clinical Research
A flourishing clinical research enterprise is critical in order to advance medical knowledge and practice for today’s patients, as well as for those in the future. The information obtained from individual trials may be like small building blocks that contribute incrementally to medical knowledge, or they may yield significant breakthroughs.
Clinical research is a collaborative enterprise and depends on the voluntary participation of patients, who may or may not derive a direct benefit from the research. Although it is not known at the start of the trial whether the individual patient will be helped, I think it is ver...
Source: PHRMA - May 4, 2015 Category: Pharmaceuticals Authors: Ali Source Type: news
Laurie Letvak
Vice President and Head of Clinical Development Policy Dr. Laurie Letvak is Vice President and Head of Clinical Development Policy at Novartis, a position she has held since June 2014.
Laurie has been with Novartis for 20 years in a variety of positions. She played a key role in the development of Gleevec® since joining the International Project Team in 2001, responsible for Global Medical Affairs. She led the development of the Medical Affairs program, which resulted in many key studies, some of which have provided the data for new indications for Gleevec ®, including Ph+ ALL and Adjuvant GIST. From 2008-2012,...
Source: PHRMA - May 4, 2015 Category: Pharmaceuticals Authors: Ali Source Type: news
Bierer on Clinical Reserach
I have often thought of what I – or my elderly mother or uninformed nephew—would wish to know before deciding about participation in clinical research, but it is nearly impossible to narrow the desired information to the one most important point. On the one hand, what any individual needs to – or wishes to – know will differ and be filtered through their personal and health situation, life experiences, nature and character. On the other hand, this is because the decision is, at its core, a nuanced choice that involves a balance between often competing factors. It is not possible, for instance, to evaluate the pot...
Source: PHRMA - May 4, 2015 Category: Pharmaceuticals Authors: Ali Source Type: news
Hinkley on Clinical Research
Participating in a clinical research study is a selfless act. Perhaps there will be personal benefit from participating in a clinical trial, but it’s not guaranteed. Every year individuals decide to advance scientific knowledge and available medical therapies by volunteering to participate in clinical research. By definition clinical research involves uncertainty and I can only imagine how that must feel. It can’t be easy. As a clinical researcher I am extremely grateful for your bravery and selflessness. You truly are a medical hero…to me and to others.
Having said that, I want to reassure you that each ...
Source: PHRMA - May 4, 2015 Category: Pharmaceuticals Authors: Ali Source Type: news
Terri Hinkley
Interim Executive DirectorTerri is the Interim Executive Director at the Association of Clinical Research Professionals (ACRP). She has recently moved into this role after spending 1.5 years as the Deputy Executive Director at ACRP with responsibility for all programs, business development, sales and marketing/communications. Terri joined ACRP in September of 2013 after 18 years in the clinical research industry. Formerly the director of clinical operations at Helix BioPharma Corp. in Aurora, Ontario, Canada, for which she successfully implemented a clinical operations program, Terri more recently put her experience ...
Source: PHRMA - May 4, 2015 Category: Pharmaceuticals Authors: Ali Source Type: news
Hohman on Clinical Research
It takes years for even the most promising experimental drugs to transition through laboratory development, clinical trials, and FDA evaluation in order to reach patients. FDA, collaborating with advocacy organizations and industry, has implemented numerous measures to accelerate drug development and evaluation. This first occurred through the Prescription Drug User Fee Act, which increased FDA resources and has been renewed five times since 1992, and progressively since then a host of expedited approval mechanisms has ensured that FDA drug evaluation reflects the current state of drug development science. These includ...
Source: PHRMA - May 4, 2015 Category: Pharmaceuticals Authors: Ali Source Type: news
Sultan on ACS-CAN event
YouTube ID: qvSol0hkkLo (Source: PHRMA)
Source: PHRMA - April 15, 2015 Category: Pharmaceuticals Authors: Ali Source Type: news
House on ACS-CAN event
YouTube ID: y6H4-UIktD0 (Source: PHRMA)
Source: PHRMA - April 15, 2015 Category: Pharmaceuticals Authors: Ali Source Type: news
Nasso on ACS-CAN event
YouTube ID: RGEs1h-TVhU (Source: PHRMA)
Source: PHRMA - April 15, 2015 Category: Pharmaceuticals Authors: Ali Source Type: news
Cancer care advocates share their thoughts on payment and delivery reform.
House on ACS-CAN event
Submitted by Ali on Wed, 04/15/2015 - 07:59
Share
Email
Print
var switchTo5x = false;var __st_loadLate = true;stLight.options({"publisher":"dr-e0d16a36-b72f-d979-d8a1-314a351971a6"});
$('#shareSocial').click(function(e) { e.preventDefault(); openSocial(); });
function openSocial() {
$('#shareSocial').toggleClass('active');
$('#social').slideToggle();
}
Sign-up for Updates
Subscribe to RSS
Nasso on ACS-...
Source: PHRMA - April 15, 2015 Category: Pharmaceuticals Authors: Ali Source Type: news
